1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Danaher Corporation

Danaher Corporation

DHR
Danaher CorporationUS flagNew York Stock Exchange
224.81
USD
-4.23
- -
158.04BMarket Cap
Danaher Corporation
DHR
(New York Stock Exchange)

Recent

price

224.81

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
19.21
23.8
26.33
26.27
18.32
20.68
24.42
22.3
24.33
25.05
31.55
34.71
36.74
32.44
32.66
34.47
35.47
Revenue per Share
2.74
3.21
3.45
3.87
3.7
4.81
3.69
3.58
3.78
4.11
4.97
8.77
9.8
6.44
5.33
5.07
5.66
Basic EPS, GAAP
2.9
3.39
4.26
4.38
4.69
4.71
4.24
4.18
4.91
4.64
7.67
9.96
10.21
7.85
7.24
7.38
7.72
Free Cash Flow per Basic Share
0.08
0.09
0.12
0.07
0.32
0.51
1.28
0.54
0.62
1.05
0.87
1.04
1.13
1.69
1.05
1.23
1.36
Dividend per Share
20.89
24.58
27.66
32.07
33.19
34.49
33.23
37.84
40.22
41.22
51.33
58.6
66.48
72.36
68.9
74.32
74.81
Book Value per Share
-0.57
-4.96
-4.06
0.14
0.92
-11.46
-18.26
-15
-6.63
-5.45
-28.42
-30.95
-11.92
-12
-13.24
-11.93
-23.03
Tangible Book Value per Share
653
676
693
696
702
698
691
696
701
715
706
715
725
736
731
713
708
Basic Weighted Avg Shares
12,550
16,090
18,260
18,283
12,867
14,434
16,882
15,519
17,049
17,911
22,284
24,802
26,643
23,890
23,875
24,568
25,107
Sales/Revenue/Turnover
16.15
15.85
16.95
17.07
15.89
14.98
16.2
16.58
17.92
18.25
18.99
25.75
28.29
21.77
20.37
19.09
20.42
Operating Margin (%)
388
635
840
851
718
881
1,128
1,117
1,178
1,189
1,775
2,062
2,132
2,166
2,352
2,447
2,531
Depreciation Expense
1,793
2,172
2,392
2,695
2,598
3,357
2,554
2,492
2,651
3,008
3,646
6,433
7,209
4,764
3,899
3,614
4,004
Net Income, GAAP
22.94
20.94
23.63
24.17
21.45
14.35
17.54
14.59
18.77
26.41
18.89
16.34
11.45
16.32
16.08
14.95
16.21
Effective Tax Rate (%)
14.29
13.5
13.1
14.74
20.19
23.26
15.13
16.06
15.55
16.79
16.36
25.94
27.06
19.94
16.33
14.71
15.95
Profit Margin (%)
2,425
2,100
3,382
4,586
4,035
1,666
-209
2,058
2,252
20,664
6,400
3,508
7,494
5,663
2,699
5,949
5,276
Working Capital
2,784
5,207
5,288
3,437
3,402
12,025
9,674
10,327
9,688
22,156
21,978
23,057
19,858
17,661
16,468
19,495
25,147
LT Debt
13,773
16,972
19,084
22,451
23,450
23,764
23,077
26,368
28,227
30,282
39,777
45,177
50,090
53,490
49,550
52,541
52,592
Total Equity
10.02
10.34
10.08
9.36
6.01
5.76
6.23
6.04
6.59
5.27
5.95
8.13
9.52
6.02
5.8
5.71
5.78
Return on Invested Capital (%)
12.09
11.75
10.76
11.12
10.11
10.94
7.52
7.23
7.38
6.8
6.74
10.16
10.62
6.96
5.92
5.53
5.71
Return on Capital (%)
14.15
14.19
13.32
13.02
11.36
14.27
10.94
10.1
9.72
10.34
10.77
15.99
15.73
9.31
7.57
7.08
7.63
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
201
923
1,411
LT Borrowings
18,416
17,561
25,147
LT Finance Leases
1,079
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
707
708
703
Market Capitalization
161,824
134,180
133,888

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
12,756
13,935
13,381
Cash, Cash Equivalents & STI
4,615
5,701
4,348
Accounts Receivable, Net
3,913
3,819
3,965
Inventories
2,489
2,608
3,260
Total Current Liabilities
6,807
7,460
8,105
Payables & Accruals
2,451
6,537
6,694
ST Debt
201
923
1,411
Deferred Revenue
1,353
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.7%
5.98%
6.04%
Free Cash Flow
7.08%
0.88%
-0.68%
Net Income, GAAP
4.38%
5.82%
-7.31%
Sales/Revenue/Turnover
5.95%
2.25%
2.9%
Total Cash Common Dividend
22.81%
18.62%
14.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,796
5,743
5,798
6,538
23,875
2025
5,741
5,936
6,053
6,838
24,568
2026
5,951
6,265
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.47
1.23
1.13
1.5
5.33
2025
1.33
0.77
1.28
1.69
5.07
2026
1.45
1.23
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.27
0.27
0.27
1.05
2025
0.27
0.32
0.32
0.32
1.23
2026
0.32
0.4
- -
- -
- -
Similar Companies
CelLBxHealth plc (CLBX.L)
Immunovia AB (IMMNOV.ST)
Rosetta Genomics Ltd. (ROSGQ)
MDxHealth S.A. (MXDHF)
Agilent Technologies, Inc. (0HAV.L)
Thalys Medical Technology Group Inc. (603716.SS)
Business
Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.

Company News

Company News APIChatGPT

  • benzinga.com

    Danaher Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

  • defenseworld.net

    Danaher Corporation $DHR Stock Bought by SteelPeak Wealth LLC

  • defenseworld.net

    Danaher Corporation $DHR Stock: IFP Advisors Inc Increases Stake

  • defenseworld.net

    Danaher Corporation $DHR Shares Bought by Birch Hill Investment Advisors LLC

  • defenseworld.net

    2,506 Danaher Corporation $DHR Shares Acquired by Forbes J M & Co. LLP

  • defenseworld.net

    15,838 Shares of Danaher Corporation $DHR Acquired by CWS Financial Advisors LLC

  • defenseworld.net

    76,426 Shares in Danaher Corporation $DHR Bought by Aull & Monroe Investment Management Corp

  • defenseworld.net

    7,604 Shares in Danaher Corporation $DHR Bought by Beaumont Asset Management L.L.C.

  • defenseworld.net

    Danaher Corporation $DHR Shares Bought by Banque Pictet & Cie SA

  • defenseworld.net

    Baugh & Associates LLC Purchases New Shares in Danaher Corporation $DHR

  • defenseworld.net

    ARS Wealth Advisors Group LLC Makes New Investment in Danaher Corporation $DHR

  • defenseworld.net

    Danaher Corporation $DHR Shares Acquired by Aspiriant LLC

  • zacks.com

    Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?

  • zacks.com

    Seeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

  • defenseworld.net

    Danaher Corporation $DHR Stock: Chiron Capital Management LLC Decreases Position

  • defenseworld.net

    Danaher Corporation $DHR Stake Increased by Cohen Klingenstein LLC

  • defenseworld.net

    Charles Schwab Trust Co Buys New Holdings in Danaher Corporation $DHR

  • defenseworld.net

    Barlow Wealth Partners LLC Purchases 2,620 Shares of Danaher Corporation $DHR

  • defenseworld.net

    2,973 Shares in Danaher Corporation $DHR Bought by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors

  • zacks.com

    These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar